Key Takeaways
In pharmaceutical formulation, combining Laser Diffraction (LD) with Particle Correlated Raman Spectroscopy (PCRS) allows researchers to move beyond bulk physical measurements to gain chemically resolved insights into multi-component blends. While LD establishes the overall volume-weighted particle size distribution, PCRS utilizes Raman identification and automated imaging to reveal exactly which chemical components—such as the active ingredient or a specific excipient—occupy those size ranges. This integrated approach empowers scientists to accurately diagnose the root cause of coarse tails or fine fractions, enabling precise interventions and robust risk management for complex drug formulations.
Read the full article here.
Overcoming the limitations of bulk analysis, combining Laser Diffraction (LD) and Particle Correlated Raman Spectroscopy (PCRS) delivers chemically resolved particle size characterization without compromising data integrity. While LD quantifies the overall Particle Size Distribution (PSD), PCRS provides the molecular identity of each size fraction, revealing whether specific formulation components occupy the fine or coarse regions.
Beyond determining physical metrics (transition to Formulation Development), this integration allows formulation scientists to generate spatially resolved, chemically annotated particle maps. Conventional sizing techniques quantify the physical landscape but lack the chemical context necessary for multi-component blends. By utilizing PCRS, R&D teams can accurately deconvolve multimodal distributions, ensuring that shifting medians or emerging fines are correctly attributed to either the excipient or the Active Pharmaceutical Ingredient (API).
Addressing the need for stringent regulatory compliance, PCRS directly supports Quality by Design (QbD) methodologies by providing actionable structural insights into multi-component blends. By specifically identifying which constituents form agglomerates versus true coarse particles, formulation developers can confidently link physical Critical Material Attributes (CMAs) to final Critical Quality Attributes (CQAs) like dissolution and bioavailability.
Moving from raw data collection to advanced control strategies (transition to R&D Innovation), R&D laboratories utilize these detailed chemical attributions to refine their development processes. Aligning with Process Analytical Technology (PAT) principles, the correlative LD-PCRS approach provides the specificity required to establish rigorous component-specific thresholds (e.g., tracking the <10 µm API fraction). This targeted characterization ensures robust process design, enhanced supplier oversight, and comprehensive risk management before a drug ever reaches the production phase.
Resolving unexplained particle clustering in complex mixtures requires precise chemical attribution to accurately diagnose formulation deviations. When a coarse tail emerges in a blend's bulk PSD, PCRS distinguishes true, oversized API particles from mixed excipient agglomerates, enabling R&D scientists to pinpoint the exact root cause of structural abnormalities and downstream segregation risks.
After diagnosing the root cause of these deviations (transition to Quality Assurance workflows), formulation scientists can apply highly targeted, defensible interventions. If the coarse mode is purely API, the solution may involve tightening sieve cuts or revising milling protocols; if it consists of mixed clusters, the focus shifts to adjusting blend energy, order of addition, or mitigating electrostatic interactions. This level of granular characterization empowers laboratories to resolve deviations strictly through data-driven science.
Do you have any questions or requests? Use this form to contact our specialists.
